Maco Pharma developped the FIRST virally inactivated human platelet lysate on the market, MultiPL’i
The amplification of stem cells in defined, standardised, xeno-free conditions represents a major challenge for the production of safe and reproducible cell therapy products . Furthermore, the regulatory environment is on constant evolution, for that reason Maco Pharma developed the first VIRALLY INACTIVATED human platelet lysate: MultiPL’i that meets the requirements of adventitious agent transmission reduction (General Chapter 5.2.12 of the European Pharmacopeia current version).
An efficient, standardized and safer* supplement to expand multiple cell types.
MultiPL’i is an efficient, standardized and safer* alternative to the FBS. As efficient and standardized as their predecessors MultiPL’ and safer* thanks to the pathogen reduction step. MultiPL’i is available in 2 distincts compositions MultiPL’30i and MultiPL’100i.
MultiPL’i benefits compared to FBS:
- Xenogenic risk free
- Enhanced cell growth kinetics and reduced supplementation
- Cost consistency and pricing stability thanks to large batches manufacturing
- Reduced cell culture cost by increasing amplification yield with less supplementation in less time
- Qualified human blood donation with virus testing and pathogen reduction ensure safety
MultiPL’30i and MultiPL’100i enhance the hBM-MSCs PROLIFERATION compared to FBS supplementation and allow reduced supplementation.
Dose effect on proliferation of human bone marrow-mesenchymal stem cells (BM-hMSCs) seeded at 2500 cells/cm2 and cultured in FBS or MultiPL’30i or MultiPL’100i for 7 days at P3 or P4, respectively.
2. Differentiation potential
hBM-MSCs cultured in MultiPL’30i and MultiPL’100i retained their differentiation potential in adipocytes and osteoblasts.
Differentiation potential of BM-hMSCs cultured in 10% FBS or 8% MultiPL’30i or MultiPL’100i at P2 for 7 days. After expansion, BM-hMSCs were cultured in the presence of specific differentiation media for 14 days and 21 days to induce adipogenic and osteogenic differentiation, respectively.
* Than their predecessors MultiPL’30 and MultiPL’100.